References
- WieldersLHLambermontVASchoutenJSPrevention of cystoid macular edema after cataract surgery in non-diabetic and diabetic patients: a systematic review and meta-analysisAm J Ophthalmol2015160596898126232601
- KimSJSchoenbergerSDThorneJEEhlersJPYehSBakriSJTopical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of OphthalmologyOphthalmology2015122112159216826123091
- HendersonBAKimJYAmentCSFerrufino-PonceZKGrabowskaACremersSLClinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatmentJ Cataract Refract Surg20073391550155817720069
- BenitahNRArroyoJGPseudophakic cystoid macular edemaInt Ophtalmol Clin2010501139153
- ErikssonUAlmABjarnhallGGranstamEMatssonAWMacular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controlsGraefes Arch Clin Exp Ophthalmol2011249334935920827486
- KreplerKBiowskiRSchreySJandrasitsKWedrichACataract surgery in patients with diabetic retinopathy: visual outcome, progres sion of diabetic retinopathy, and incidence of diabetic macular oedemaGraefes Arch Clin Exp Ophthalmol2002240973573812271370
- BakerCWAlmukhtarTBresslerNMDiabetic Retinopathy Clinical Research Network Authors/Writing CommitteeMacular edema after cataract surgery in eyes without preoperative central involved diabetic macular edemaJAMA Ophthalmol2013131787087923599174
- DowlerJGFSehmiKSHykinPGHamiltonAMThe natural history of macular edema after cataract surgery in diabetesOphthalmology1999106466366810201584
- ChuCJJohnstonRLBuscombeCSallamABMohamedQYangYCUnited Kingdom Pseudophakic Macular Edema Study Group OphthalmologyRisk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyesOphthalmology2016123231632326681390
- RossettiLChaudhuriJDickersinKMedical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta-analysisOphthalmology199810533974059499767
- KesselLTendalBJørgensenKJPost-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic reviewOphthalmology2014121101915192424935281
- European Medical Agency Assessment Report: Nevenac EMA/CHMP/167525/2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000818/WC500212717.pdfAccessed October 5, 2016
- ILEVRO™ (nepafenac ophthalmic suspension 0.3%) [package insert]Fort Worth, TXAlcon Laboratories, Inc2014 Available from: http://ecatalog.alcon.com/PI/Ilevro_us_en.pdfAccessed April 27, 2016
- KeTLGraffGSpellmanJMYanniJMNepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation200024437138410850858
- WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
- ChastainJESandersMECurtisMADistribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eyeExp Eye Res2016145586726474497
- SinghRAlpernLJaffeGJEvaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathyClin Ophthalmol201261259126922927737
- PollackAStaurenghiGSagerDMukeshBReiserHSinghRProspective randomized clinical trial to evaluate the safety and efficacy of nepafenac treatment for the prevention of macular edema associated with cataract surgery in patients with diabetic retinopathyBr J Ophthalmol20161527378485
- SinghRLehmannRMartelJNepafenac 0.3% following cataract surgery in patients with diabetic retinopathy: results of two randomized Phase 3 studiesOphthalmology Epub201734
- MiyakeKOtaIMiyakeGNumagaJNepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgeryJ Cataract Refract Surg20113791581158821855758
- HariprasadSMCallananDGaineySHeYGWarrenKCystoid and diabetic macular edema treated with nepafenac 0.1%J Ocul Pharmacol Ther200723658559018001248
- American Medical Association2016Registry Individual Measure Flow-Measure #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery – National Quality Strategy Domain: Effective Clinical Care Available from: http://www.mdinteractive.com/files/uploaded/file/CMS2016/2016_PQRS_Measure_191_11_17_2015.pdfAccessed on May 6, 2016
- MittraRABorrilloJLDevSMielerWFKoenigSBRetinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitusArch Ophthalmol2000118791291710900103
- BakerCWAlmukhtarTBresslerNMMacular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edemaJAMA Ophthalmol2013131787087923599174
- LundströmMManningSBarryPSteneviUHenryYRosenPVisual outcome of cataract surgery; study from the European registry of quality outcomes for cataract and refractive surgeryJ Cataract Refract Surg201339567367923499065
- MorrisDFraserSDGrayCCataract surgery and quality of life implicationsClin Interv Aging20072110510818044082
- FergusonVMGSpaltonDJContinued breakdown of the blood aqueous barrier following cataract surgeryBr J Ophthalmol19927684534561390524
- PollackALeibaHBukelmanAOliverMCystoid macular oedema following cataract extraction in patients with diabetesBr J Ophthalmol19927642212241390489
- HenricssonMHeijlAJanzonLDiabetic retinopathy before and after cataract surgeryBr J Ophthalmol19968097897938942374
- ZaczekAOlivestedtGZetterstromCVisual outcome after phacoemulsification and IOL implantation in diabetic patientsBr J Ophthalmol19998391036104110460771
- WolfEJBraunsteinAShihCBraunsteinREIncidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJ Cataract Refract Surg20073391546154917720068
- MathysKCCohenKLImpact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedemaEye (Lond)2010241909619229275
- AlmeidaDRPKhanZXingLProphylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsificationJ Cataract Refract Surg20123891537154322795976
- TzelikisPFVieiraMHidaWtComparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised studyBr J Ophthalmol201599565465825385061
- AlmeidaDRPJohnsonDHollandsHEffect of prophylactic nonsteroidal anti-inflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgeryJ Cataract Refract Surg2008341646918165083
- AsanoSMiyakeKOtaIReducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%J Cataract Refract Surg2008341576318165082
- HirneissCNeubauerASKampikASchonfeldCLComparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked studyGraefes Arch Clin Exp Ophthalmol2005243876877315756571
- HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked studyJ Cataract Refract Surg2002281939911777716
- WangQWYaoKXuWBromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsificationOphthalmologica2013229418719423429038
- DonnenfeldEDHollandEJSolomonKDA multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgeryAm J Ophthalmol2011152460961721704965
- DonnenfeldEDPerryHDWittpennJRSolomonRNattisAChouTPreoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic response curveJ Cataract Refract Surg20063291474148216931258